Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR. Wodal W, et al. Among authors: portsmouth d. Vaccine. 2012 Jun 29;30(31):4625-31. doi: 10.1016/j.vaccine.2012.04.102. Epub 2012 May 10. Vaccine. 2012. PMID: 22580355
Developing cell culture-derived pandemic vaccines.
Barrett PN, Portsmouth D, Ehrlich HJ. Barrett PN, et al. Among authors: portsmouth d. Curr Opin Mol Ther. 2010 Feb;12(1):21-30. Curr Opin Mol Ther. 2010. PMID: 20140813 Review.
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN. Aichinger G, et al. Among authors: portsmouth d. Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12. Vaccine. 2011. PMID: 22001875 Clinical Trial.
Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Ehrlich HJ, et al. Among authors: portsmouth d. Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13. Vaccine. 2012. PMID: 22172502 Clinical Trial.
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN. Ehrlich HJ, et al. Among authors: portsmouth d. Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1. Vaccine. 2012. PMID: 22475864 Clinical Trial.
A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK. Sabarth N, et al. Among authors: portsmouth d. Vaccine. 2012 Aug 10;30(37):5533-40. doi: 10.1016/j.vaccine.2012.06.043. Epub 2012 Jun 29. Vaccine. 2012. PMID: 22749797
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.
van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G. van der Velden MV, et al. Among authors: portsmouth d. J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16. J Infect Dis. 2014. PMID: 24041789 Clinical Trial.
36 results